More efficient screening for preclinical Alzheimer's clinical trials using mixture of experts
Blood plasma biomarkers identifying Alzheimer's disease (AD) neuropathology offer accessible and scalable alternatives to lumbar puncture and positron emission tomography (PET) scans, with potential efficiency gains in clinical trial recruitment.